<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00778193</url>
  </required_header>
  <id_info>
    <org_study_id>Healing Study</org_study_id>
    <secondary_id>GA319181</secondary_id>
    <nct_id>NCT00778193</nct_id>
  </id_info>
  <brief_title>Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers</brief_title>
  <acronym>Lesions2</acronym>
  <official_title>A Randomized, Blinded, Placebo-Controlled Study of the Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on Gastroduodenal Healing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Associates of New York, LLP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Research Associates of New York, LLP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastroduodenal ulcers are extremely common in the community today. Though much has been
      written and observed concerning how ulcers form, not much has been described in the human
      model concerning how these ulcers heal. As numerous patients already suffer from
      gastrointestinal ulcers, further clarification of ulcer healing would be valuable in the
      treatment and management of these patients. The goal of this study is to investigate the
      effects of naproxen, aspirin, celecoxib, and clopidogrel on biopsy-induced gastroduodenal
      lesions in order to elucidate the mechanisms of ulcer healing. This single site,
      single-blind, randomized, placebo-controlled, one-week prospective study will examine ulcer
      healing through endoscopic, immunohistologic, and molecular PCR modalities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to assess the extent of healing of the biopsy sites, a 12-point scale was developed
      and validated.

      After all of the procedures were complete, this scale was used to measure the effects of the
      study drugs on the healing of the biopsy-induced ulcers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Gastroduodenal Ulcer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>1 tablet 500mg BID for 8 days</description>
    <arm_group_label>Naproxen</arm_group_label>
    <other_name>naprosyn</other_name>
    <other_name>naproxen sodium</other_name>
    <other_name>Aleve</other_name>
    <other_name>Anaprox</other_name>
    <other_name>Miranax</other_name>
    <other_name>Naprogesic</other_name>
    <other_name>Naprelan</other_name>
    <other_name>Proxen</other_name>
    <other_name>Synflex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>1 tablet 81mg QD for 8 days</description>
    <arm_group_label>Aspirin</arm_group_label>
    <other_name>ASA</other_name>
    <other_name>Bayer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>1 capsule 200mg QD for 8 days</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule BID for 8 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Age 18-75

          -  Use of appropriate form of birth control for women of childbearing potential.

        Exclusion Criteria:

          -  H pylori infection

          -  Use of NSAIDs within 2 weeks prior to start of enrollment

          -  Use of antacids or H-2 blockers within 2 weeks of enrollment

          -  Use of PPIs within 30 days of enrollment

          -  Corticosteroid use within 60 days of enrollment

          -  History of a previous ulcer

          -  Diagnosis of a bleeding diathesis or use of warfarin within 60 days of enrollment

          -  Use of cigarettes within 6 months of enrollment

          -  Consumption of &gt;3 alcoholic beverages per day

          -  Hypersensitivity or allergy to NSAIDs, clopidogrel, or corn starch, or any
             contraindications to ingesting those substances

          -  The presence of an ulcer at a baseline endoscopy

          -  Endoscopically severe gastritis or duodenitis baseline endoscopy

          -  Moderate or severe inflammation located within the duodenal bulb or within 2cm of the
             pyloric channel at a baseline endoscopy

          -  Any gastroduodenal tumor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Aisenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Associates of New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Associates of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Desai JC, Sanyal SM, Goo T, Benson AA, Bodian CA, Miller KM, Cohen LB, Aisenberg J. Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: a randomized, double-blind, placebo-controlled study. Dig Dis Sci. 2008 Aug;53(8):2059-65. doi: 10.1007/s10620-007-0127-4. Epub 2008 Jan 26.</citation>
    <PMID>18224442</PMID>
  </reference>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2008</study_first_posted>
  <last_update_submitted>October 22, 2008</last_update_submitted>
  <last_update_submitted_qc>October 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>James Asienberg, MD</name_title>
    <organization>Research Associates of New York</organization>
  </responsible_party>
  <keyword>NSAID</keyword>
  <keyword>ulcer</keyword>
  <keyword>gastroduodenal ulcer</keyword>
  <keyword>naproxen</keyword>
  <keyword>aspirin</keyword>
  <keyword>ASA</keyword>
  <keyword>celecoxib</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>healing</keyword>
  <keyword>Cyclooxygenase 2 Inhibitors</keyword>
  <keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
  <keyword>Platelet Aggregation Inhibitors</keyword>
  <keyword>Wound Healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

